323-OR: SGLT2 Inhibition Promotes Myocardial Ketone Utilization in the Normal and Failing Heart
GOEDEKE L, LEE J, MA Y, HU X, ZHANG J, DONG J, GALSGAARD K, GUERRERA N, HAEDERSDAL S, ZHANG X, PERRY R, CLINE G, YOUNG L, SHULMAN G. 323-OR: SGLT2 Inhibition Promotes Myocardial Ketone Utilization in the Normal and Failing Heart. Diabetes 2021, 70 DOI: 10.2337/db21-323-or.Peer-Reviewed Original ResearchPlasma glucose concentrationDAPA treatmentHeart failureAwake male Sprague-Dawley ratsMajor adverse cardiovascular eventsMale Sprague-Dawley ratsRecent clinical outcome studiesAdverse cardiovascular eventsHeart failure ratsType 2 diabetesClinical outcome studiesSprague-Dawley ratsGlucose concentrationΒOHB levelsCardiovascular eventsCardiovascular benefitsVehicle treatmentPermanent ligationSGLT2 inhibitorsCoronary arteryControl ratsKetone utilizationDawley ratsAcute effectsFailing Heart